Guardant Health (GH) to Release Quarterly Earnings on Wednesday

Key Points

• Guardant Health is set to announce its Q3 2025 earnings on October 29, 2025, with analysts predicting a loss of ($0.48) per share and revenue of $235.715 million.
• In its previous quarterly results, Guardant Health beat earnings expectations with a reported loss of ($0.44) per share and revenue of $232.09 million, marking a 31% increase in revenue year-over-year.
• The company's stock, currently down 3.8%, has a market capitalization of $8.42 billion and analysts have a consensus rating of "Moderate Buy" with an average target price of $65.86.

Guardant Health (NASDAQ:GH - Get Free Report) is projected to announce its Q3 2025 results after the market closes on Wednesday, October 29th. Analysts expect the company to announce earnings of ($0.48) per share and revenue of $235.7150 million for the quarter. Guardant Health has set its FY 2025 guidance at EPS.Investors can check the company's upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Wednesday, October 29, 2025 at 4:30 PM ET.

Guardant Health (NASDAQ:GH - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.08. The company had revenue of $232.09 million during the quarter, compared to analysts' expectations of $211.19 million. During the same quarter in the prior year, the company earned ($0.84) earnings per share. The firm's revenue was up 31.0% compared to the same quarter last year. On average, analysts expect Guardant Health to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Guardant Health Stock Down 3.8%

Shares of NASDAQ:GH opened at $67.51 on Wednesday. Guardant Health has a 52-week low of $20.14 and a 52-week high of $70.33. The stock's fifty day simple moving average is $61.62 and its 200-day simple moving average is $51.28. The company has a market capitalization of $8.42 billion, a P/E ratio of -20.15 and a beta of 1.53.

Insider Transactions at Guardant Health

In other news, Director Medina Manuel Hidalgo sold 2,165 shares of the stock in a transaction dated Friday, September 12th. The stock was sold at an average price of $54.16, for a total value of $117,256.40. Following the completion of the sale, the director owned 851 shares in the company, valued at approximately $46,090.16. This trade represents a 71.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Helmy Eltoukhy sold 300,000 shares of the firm's stock in a transaction that occurred on Tuesday, September 9th. The shares were sold at an average price of $59.45, for a total value of $17,835,000.00. Following the sale, the chief executive officer owned 2,123,499 shares of the company's stock, valued at approximately $126,242,015.55. This trade represents a 12.38% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 302,691 shares of company stock valued at $17,984,628. Insiders own 6.10% of the company's stock.

Institutional Investors Weigh In On Guardant Health

Hedge funds have recently bought and sold shares of the business. Empowered Funds LLC acquired a new stake in Guardant Health during the 1st quarter valued at approximately $274,000. Occudo Quantitative Strategies LP acquired a new stake in Guardant Health during the 2nd quarter valued at approximately $476,000. Bayesian Capital Management LP acquired a new stake in Guardant Health during the 2nd quarter valued at approximately $762,000. Tower Research Capital LLC TRC grew its stake in Guardant Health by 284.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 15,087 shares of the company's stock valued at $785,000 after purchasing an additional 11,163 shares in the last quarter. Finally, CANADA LIFE ASSURANCE Co grew its stake in Guardant Health by 8.1% during the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 32,485 shares of the company's stock valued at $1,694,000 after purchasing an additional 2,421 shares in the last quarter. Institutional investors and hedge funds own 92.60% of the company's stock.

Analysts Set New Price Targets

Several analysts have recently issued reports on GH shares. William Blair restated an "outperform" rating on shares of Guardant Health in a research report on Thursday, September 25th. Wells Fargo & Company started coverage on Guardant Health in a research report on Monday, September 22nd. They set an "overweight" rating and a $72.00 target price on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Guardant Health in a research note on Wednesday, October 8th. Scotiabank upped their price target on Guardant Health from $57.00 to $60.00 and gave the stock a "sector outperform" rating in a research note on Thursday, July 31st. Finally, UBS Group upped their price target on Guardant Health from $70.00 to $80.00 and gave the stock a "buy" rating in a research note on Thursday, September 25th. Twenty-three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $65.86.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.